AAPL 207.5 +0.52 (+0.25%)MSFT 125.42 +0.48 (+0.38%)FB 183.67 +0.21 (+0.11%)ZNGA 5.62 +0.1 (+1.81%)NVDA 190.7 -0.66 (-0.34%)WBA 53.19 -0.53 (-0.99%)GOOG 1264.39 -1.93 (-0.15%)PIH 5.25 -0.05 (-0.94%)
AAPL 207.5 +0.52 (+0.25%)MSFT 125.42 +0.48 (+0.38%)FB 183.67 +0.21 (+0.11%)ZNGA 5.62 +0.1 (+1.81%)NVDA 190.7 -0.66 (-0.34%)WBA 53.19 -0.53 (-0.99%)GOOG 1264.39 -1.93 (-0.15%)PIH 5.25 -0.05 (-0.94%)

Cash Flow ACER Quote Acer Therap

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -8 -14 -21
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 0 0 1
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 0 1
OtherWorkingCap -2 0 0
OtherNonCashIte 0 0 0
NetCashProvided -9 -14 -17
InvestmentsInPP 0 0 0
AcquisitionsNet 0 1 0
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 1 0
DebtIssued 0 6 0
DebtRepayment 0 0 0
CommonStockIssu 0 22 43
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 0 0
NetCashProvided 0 27 43
NetChangeInCash -9 14 26
CashAtBeginning 13 2 16
CashAtEndOfPeri 3 16 42
Acer Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Acer Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.